Publications by authors named "J Medioni"
Purpose: Trastuzumab Deruxtecan (T DXD), a new antibody drug conjugate is a new treatment option for 2nd line metastatic breast cancer (MBC) for HER2 + or HER2 low tumors. Palliative or ablative radiotherapy (RT) may be required in patients who are being treated with T-DXd. However there is a lack of evidence regarding the safety profile of combining T-DXd with RT.
View Article and Find Full Text PDFImportance: Testing for homologous recombination deficiency is required for the optimal treatment of high-grade epithelial ovarian cancer. The search for accurate biomarkers is ongoing.
Objective: To investigate whether progression-free survival (PFS) and overall survival (OS) of patients with high-grade epithelial ovarian cancer treated with maintenance olaparib or placebo differed between patients with a tumor BRCA-like genomic profile and patients without a tumor BRCA-like profile.
Article Synopsis
- The POD1UM-203 study tested retifanlimab, a monoclonal antibody that targets PD-1, on patients with specific solid tumors that have had successful responses to immune checkpoint therapies in the past.
- A total of 121 patients with various cancers (melanoma, NSCLC, urothelial carcinoma, and renal cell carcinoma) were treated, showing overall response rates ranging from 23.5% to 40% across different cohorts.
- Results indicate that retifanlimab has durable anti-tumor effects and a safety profile similar to other PD-(L)1 inhibitors, supporting further investigation in solid tumors.
Article Synopsis
- The study examines how individual differences in drug absorption (pharmacokinetics) impact the effectiveness and side effects of cabozantinib in patients with metastatic renal cell carcinoma (mRCC).
- Out of 78 patients analyzed, 67% experienced dose-limiting toxicity, and higher drug concentration in the blood was identified as a significant risk factor for these side effects.
- The research suggests that monitoring drug levels early in treatment could help optimize cabozantinib therapy, particularly for frail patients starting on lower doses.
Introduction: Considering the growing interest in matched cancer treatment, our aim was to evaluate the ability of a comprehensive genomic profiling (CGP) assay to propose at least one targeted therapy given an identified genomic alteration or signature (actionability), and to collect the treatment modifications based on the CGP test results in clinical practise for solid tumors.
Methods: This retrospective, multicentre French study was conducted among 25 centres that participated in a free of charge program between 2017 and 2019 for a tissue CGP test. Data were collected on the patient, disease, tumor genomic profile, treatment suggested in the report (related to the genomic profile results) and subsequent therapeutic decisions according to the physician's declaration.